Paul Tudor Jones Chinook Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

  • $19.2 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$18.63 - $27.35 $115,207 - $169,132
-6,184 Reduced 19.7%
25,211 $661,000
Q3 2022

Nov 14, 2022
SELL
$17.51 - $23.37 $56,172 - $74,970
-3,208 Reduced 9.27%
31,395 $617,000
Q2 2022

Aug 15, 2022
BUY
$12.59 - $18.8 $435,651 - $650,536
34,603 New
34,603 $605,000

Others Institutions Holding KDNY

# of Institutions
5
Shares Held
234K
Call Options Held
0
Put Options Held
0
View Full List

About CHINOOK THERAPEUTICS, INC.

KDNY Quotes by TradingView
  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email